Peptide-3

General Information


DRACP ID  DRACP00337

Peptide Name   Peptide-3

Sequence  RRRRRRRRGGCX

Sequence Length  12

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Coupling peptide



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HL-60 Adult acute myeloid leukemia; Acute myeloid leukemia Leukemia IC50=6.24 µM MTT assay 3 h 1
NCI-H358 Minimally invasive lung adenocarcinoma Carcinoma IC50=8.41 µM MTT assay 3 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  X(12)=Pemetrexed

Chiral  L



Physicochemical Information


Formula  C55H107N35O11S

Absent amino acids  ADEFHIKLMNPQSTVWY

Common amino acids  R

Mass  177310

Pl  12.98

Basic residues  8

Acidic residues  0

Hydrophobic residues  0

Net charge  8

Boman Index  -11620

Hydrophobicity  -285.83

Aliphatic Index  0

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 22076954

Title  New pemetrexed-peptide conjugates: synthesis, characterization and in vitro cytostatic effect on non-small cell lung carcinoma (NCI-H358) and human leukemia (HL-60) cells

Doi 10.1002/psc.1407

Year  2011

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.